Features of triple-negative breast cancer Analysis of 38,813 cases from the national cancer database

Medicine (United States)

Volumn 95, Issue 35, 2016, Pages

  Plasilova, Magdalena L ^a   Hayse, Brandon ^a   Killelea, Brigid K ^a   Horowitz, Nina R ^a   Chagpar, Anees B ^a   Lannin, Donald R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer molecular type; National cancer database; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER REGISTRY; CONTROLLED STUDY; DATA BASE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UNITED STATES; AFRICAN AMERICAN; AGE; BREAST NEOPLASMS, MALE; CANCER GRADING; CARCINOMA; CAUCASIAN; ETHNOLOGY; FACTUAL DATABASE; HISPANIC; INCIDENCE; LYMPH NODE METASTASIS; PATHOLOGY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR INVASION;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; BREAST NEOPLASMS, MALE; CARCINOMA; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; SEX FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; UNITED STATES;

EID: 84987738965     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004614     Document Type: Article

References (21)

1. Newman LA, Reis-Filho JS, Morrow M, et al. The 2014 society of surgical oncology susan g. Komen for the cure symposium: triplenegative breast cancer. Ann Surg Oncol 2015;22:874-82.
2. Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011;127:713-20.
3. Ueno NT, Zhang D. Targeting EGFR in triple negative breast cancer. J Cancer 2011;2:324-8.
4. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
5. Duffy MJ,McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012;131:2471-7.
6. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012;118:5463-72.
7. Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 2015;313:165-73.
8. Gangi A, Chung A, Mirocha J, et al. Breast-conserving therapy for triplenegative breast cancer. JAMA Surg 2014;149:252-8.
9. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012;226:84-96.
10. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23(suppl 6):vi7-12.
11. Amirikia KC, Mills P, Bush J, et al. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 2011;117:2747-53.
12. Parise C, Caggiano V. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. Cancer Epidemiol 2014;38:556-62.
13. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 2014;144:1-10.
14. Gangi A, Mirocha J, Leong T, et al. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases. Ann Surg Oncol 2014;21:4098-103.
15. Wiechmann L, SampsonM, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009;16:2705-10.
16. Ugras S, Stempel M, Patil S, et al. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol 2014;21:3780-6.
17. Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29:2852-8.
18. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72.
19. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
20. Killelea BK, Yang VQ, Wang SY, et al. Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the National Cancer Data Base. J Clin Oncol 2015;33:4267-76.
21. Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 2015;121:2544-52.